Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pharmacokinetic monitoring Clear all

Conditions: Crohn Disease
Interventions: RoadMAB, Infliximab; Device · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 22 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 8 more

Conditions: Nicotine Dependence, Tobacco Toxicity, Nicotine Dependence, Cigarettes, Cardiovascular Risk Factor, Nicotine Withdrawal
Interventions: SREC; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Congenital Heart Disease
Interventions: Phenoxybenzamine, Standard surgical approach; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: Up to 6 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CTLA4-IgG4m (RG2077), Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Type 1 Diabetes
Interventions: Multiplex pharmacokinetic profiling, Continuous insulin monitoring; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 44 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fungal Infection
Interventions: Voriconazole; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers, Chemical Terrorism, Chemical Warfare
Interventions: Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Renal Failure, Bacterial Infections, Critical Illness
Interventions: Ceftazidime-avibactam; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: MRSA
Interventions: Duration of therapy, Direct Cost, Pharmacokinectic Monitoring, Hospital stay; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, HIDA; Drug · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2; Diagnostic Test · Drug · Device
Lead sponsor: Cari Health Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lemon Grove, California

Conditions: Renal Replacement Therapy, Pharmacokinetics
Interventions: Cefazolin; Drug
Lead sponsor: Drexel University; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Transplantation, Renal, Immunosuppression
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Neonatal Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Infant,Premature, Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions: L-Citrulline; Drug
Lead sponsor: University of Utah; Other
Eligibility: 14 Days to 3 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Clostridium Difficile Infection
Interventions: Cadazolid, Vancomycin capsule, Vancomycin solution; Drug
Lead sponsor: Actelion; Industry
Eligibility: Up to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more

Conditions: Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2; Diagnostic Test · Drug · Device
Lead sponsor: Cari Health Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lemon Grove, California

Conditions: Asthma
Interventions: GSK573719 Active treatment or Placebo, GSK573719 (Sub-group cohort), Salbutamol/Albuterol; Drug · Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Newport Beach, California • Sunset, Louisiana • Bethesda, Maryland + 9 more

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: Pediatric Acute Lung Injury
Interventions: Pharmacokinetic Sampling and pharmacogenetic analysis; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Precise Infliximab Exposure and Pharmacodynamic Control

Cigarette Harm Reduction With Electronic Cigarette Use

Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

Busulfan and Cyclophosphamide Followed By ALLO BMT

Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

To Evaluate the Impact of MRSA Nasal Screen Implementation.

Pilot Study for Patients With Poor Response to Deferasirox

Assessment of Methadone Dose Taken

Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression

The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Methadone Dose Monitoring With a Remote Medication Monitor

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

Pharmacologic Impact on Sedation Assessments